Aman Kant

I’ve spent nearly two decades at the intersection of biotechnology and artificial intelligence, scaling innovation across the biopharmaceutical value chain. My career spans start-up formation and growth, AI-enabled drug discovery, strategic deal-making, capital formation, and company leadership. I have built and scaled AI-driven platforms and biotech pipelines, co-founding two companies applying AI as a force multiplier to accelerate drug discovery and development across immune-mediated inflammatory diseases and other complex biology settings. Today, as President of Invea Therapeutics, I lead corporate strategy, operations, and development execution — from financing and portfolio prioritization, to translational strategy, clinical planning, external partnerships, and investor engagement. My work integrates cutting-edge AI technologies with rigorous translational science and clinical design to unlock novel disease solutions for patients with immune-driven conditions. Focus Areas & Experience: • Company building & leadership in AI-enabled biotech • Portfolio strategy across discovery, translational, and clinical stages • Strategic partnerships, deal-making, and in/out-licensing • Securing private and public capital, growth financing, and investor relations • Designing & advancing immunology pipelines with strong KOL engagement • Orchestrating CDMO/CRO partnerships and clinical execution frameworks • Applying machine learning to accelerate asset identification & development Across my career, I have executed multiple strategic alliances, technology licensing deals, and multimillion-dollar commercial agreements enabling AI adoption across the pharmaceutical R&D continuum. I am fortunate to work alongside exceptional scientific, clinical, and business teammates who share a singular mission: delivering innovative therapies that meaningfully improve patient lives.